Years of research into the molecular mechanisms behind glioblastoma, a highly lethal brain cancer with limited treatment options, have sparked a ground-breaking discovery at The Hospital for Sick Children (SickKids) – a designer peptide targeting the EAG2-Kvβ2 protein-protein interaction, which has shown promising therapeutic efficacy in preclinical models.
Recognizing the potential of this designer peptide to transform glioblastoma treatment, SickKids’ Industry Partnerships & Commercialization (IP&C) office is working with Dr. Xi Huang to propel the designer peptide to the next stage of development. Through internal funding and strategic guidance from its business development team, IP&C is enabling the completion of essential preclinical studies and expediting the journey from laboratory discovery to clinical trials. IP&C is also working to secure investments and partnerships that support our goal of revolutionizing the future of glioblastoma therapy.
Read the full publication in Nature Cancer here.
Click here to learn more about the research journey that led to this promising innovation.